Spring naar content

Máxima Butterfly MSCA program: looking for 28 PhD students in pediatric oncology 

FAQ

For frequently asked questions, please follow the “read more” button on the right.

How to apply

The application must be submitted via www.maximabutterfly.com before January 31st 2023 by 23:59 hours CET by using the electronic application form. Please follow the guidelines in the PDF documents below.

Download PDF

Timeline

current vacancies

Máxima Butterfly MSCA program: looking for 28 PhD students in pediatric oncology (Netherlands)

Read more

17. Artificial intelligence to enhance radiotherapy treatment planning for children with renal tumors.

Read more

16. Genetic susceptibility and prevention of cisplatin-induced hearing loss in childhood cancer patients

Read more

12. A game of hide and seek: targeting neuroblastoma’s escape from immunotherapy

Read more

14A. Immune Profiling in Pediatric Cancer (1)

Read more

14B. Immune Profiling in Pediatric Cancer (2)

Read more

15A. Liquid biopsies in neuroblastoma, focus on cell-free DNA

Read more

15B. Liquid biopsies for precision medicine

Read more

18A. Diagnostic radiopharmaceuticals for neuroblastoma tumors

Read more

18B. Targeting the SSR2A receptor with [68]Ga-SATO in NBL patients

Read more

4A. Improving imaging techniques for childhood craniopharyngioma to better predict hypothalamic outcome.

Read more

4B. Biomarkers for early detection of bacterial infection in children with cancer

Read more

5A. Crossing the blood-brain barrier for local immune modulation of the tumour micro-environment by innovative drug delivery methods

Read more

5B. Crossing barriers with multi-drug therapy in high-grade brain tumours

Read more

6A. ALL, leukemic niche and oncogenomics

Read more

6B. Oncogenetic lesions affecting susceptibility to (immuno)therapy in ALL

Read more

7A. The osteochondral niche: how acute lymphoblastic leukaemia cells reshape skeletal stem cell differentiation to create a supportive and protective niche?

Read more

7B. RAS signalling in the leukemic niche

Read more

28A. Advancing cellular immunotherapies for Diffuse Midline Glioma using BEHAV3D, a multi-omics 3D image-based platform

Read more

28B. Advancing DMG-midbrain organoids to model crosstalk between DMG and the human brain microenvironment

Read more

9A. Amino acid depletion therapies for T cell Acute Lymphoblastic Leukemia

Read more

9B. Identifying synthetic lethal combination therapies for TP53 deleted ALL using isogenic cell line models

Read more

10A. Characterization of the immune microenvironment of rhabdomyosarcoma for the development of immunotherapy

Read more

10B. Immunomodulation of SWI/SNF-mutated pediatric malignancie

Read more

11A. Normal and aberrant germ cell development

Read more

11B. Germ cell tumors: optimal diagnosis and follow up based on understanding epidemiology and pathogenesis.

Read more

13. Targeting aberrant ATRX to identify new treatment options for Neuroblastoma

Read more

19A. The use of organotypic tissue slices for assessing prevention against treatment-induced side-effects via nutritional preconditioning interventions

Read more

19B. Aging-related transcription stress in chemotherapy-induced Dementia’s

Read more

20A. Psychosocial risk screening across the trajectory of childhood cancer treatment

Read more

20B. Implementation of psychosocial risk screening for children with cancer and their parents during and after treatment

Read more

21A. DIS3L2-mediated Wilms tumor predisposition and the role of non-coding RNAs

Read more

21B. Tumor-based molecular signatures of childhood cancer predisposition

Read more

26A. Tracking the origin of childhood cancer

Read more

26B. The mutational consequences of cancer treatment and the evolution towards therapy-related leukaemia

Read more

22A. Risk and protective factors of neurocognitive development in young children with cancer

Read more

22B. Machine learning approaches to improve prediction of neuropsychological outcome in pediatric cancer groups

Read more

23A. A life without blood: Single-cell analysis of childhood myelodysplastic syndrome to uncover therapeutic targets

Read more

23B. Clonal evolution and therapeutic vulnerability of UBTF-mutated MDS/AML

Read more

24A. Immunomodulation of Ewing sarcoma

Read more

24B. The transforming mechanism of Small Round Cell sarcomas

Read more

25A. Exploiting genetic interactions for modelling regulatory networks in pediatric cancer

Read more

25B. Untangling somatic structural variation in pediatric cancers

Read more

27A. Functional characterization of microproteins in pediatric cancers

Read more

27B. Childhood cancer-specific proteins as targets for immunotherapy

Read more

3A. Immuno monitoring of pediatric brain tumours

Read more

3B. Exploring CAR-T cell therapy for pediatric brain tumours

Read more

2B. Elucidating role of BAP1 in fibrolamellar carcinoma

Read more

2A. Novel in vitro human models to investigate brain development and cancer

Read more

8A. Developing new therapies for acute lymphoblastic leukaemia based upon molecular genetic abnormalities and immunotherapeutic targets

Read more

8B. Improving therapy for childhood ALL by therapeutic drug monitoring

Read more

1A. R-loops in pediatric brain tumors: from cause to cure?

Read more

1B. Genetically engineered brain tumour organoids for preclinical research

Read more